Glycolytic enzymes PGK1 and PKM2 as novel transcriptional targets of PPARγ in breast cancer pathophysiology

Peroxisome proliferator-activated receptor γ (PPARγ) is a nuclear receptor and plays important roles in breast cancer cell proliferation. The complexity of the underlying biochemical and molecular mechanisms of breast cancer and the involvement of PPARγ in breast cancer pathophysiology are unclear. In this study, we carried out prediction of the peroxisome proliferator response element (PPRE) motifs in 2332 genes reported to be involved in breast cancer in literature. A total of 178 genes were found to have PPRE (DR1/DR2) and/or PPAR-associated conserved motif (PACM) motifs. We further constructed protein-protein interaction network, disease gene network and gene ontology (GO) analyses to identify novel key genes for experimental validation. We identified two genes in the glycolytic pathway (phosphoglycerate kinase 1 (PGK1) and pyruvate kinase M2 (PKM2)) at the ATP production steps and experimentally validated their repression by PPARγ in two breast cancer cell lines MDA-MB-231 and MCF-7. Further analysis suggested that this repression leads to decrease in ATP levels and apoptosis. These investigations will help us in understanding the molecular mechanisms by which PPARγ regulates the cellular energy pathway and the use of its ligands in human breast cancer therapeutics.

[1]  Lihua Lai,et al.  Cyclosporine A inhibits breast cancer cell growth by downregulating the expression of pyruvate kinase subtype M2. , 2012, International journal of molecular medicine.

[2]  H. Dvorak,et al.  Concordant release of glycolysis proteins into the plasma preceding a diagnosis of ER+ breast cancer. , 2012, Cancer research.

[3]  M. Vinciguerra,et al.  ARNTL2 and SERPINE1: potential biomarkers for tumor aggressiveness in colorectal cancer , 2012, Journal of Cancer Research and Clinical Oncology.

[4]  M. Birnbaum,et al.  PPARγ contributes to PKM2 and HK2 expression in fatty liver , 2012, Nature Communications.

[5]  Mary Goldman,et al.  The UCSC Genome Browser database: extensions and updates 2011 , 2011, Nucleic Acids Res..

[6]  F. Church,et al.  Peroxisome Proliferator-Activated Receptor-γ Ligands Alter Breast Cancer Cell Motility through Modulation of the Plasminogen Activator System , 2011, Journal of oncology.

[7]  Kishore R. Sakharkar,et al.  PPARγ disease gene network and identification of therapeutic targets for prostate cancer , 2011, Journal of drug targeting.

[8]  Tsippi Iny Stein,et al.  In-silico human genomics with GeneCards , 2011, Human Genomics.

[9]  Kara Dolinski,et al.  The BioGRID Interaction Database: 2011 update , 2010, Nucleic Acids Res..

[10]  Omar Gaci,et al.  A Topological Description of Hubs in Amino Acid Interaction Networks , 2010, Adv. Bioinformatics.

[11]  E. Gottlieb,et al.  Targeting metabolic transformation for cancer therapy , 2010, Nature Reviews Cancer.

[12]  Anushya Muruganujan,et al.  PANTHER version 7: improved phylogenetic trees, orthologs and collaboration with the Gene Ontology Consortium , 2009, Nucleic Acids Res..

[13]  M. Sakharkar,et al.  Computational identification and experimental validation of PPRE motifs in NHE1 and MnSOD genes of Human , 2009, BMC Genomics.

[14]  C. Laudanna,et al.  Analyzing biological network parameters with CentiScaPe , 2009, Bioinform..

[15]  Gang Feng,et al.  From disease ontology to disease-ontology lite: statistical methods to adapt a general-purpose ontology for the test of gene-ontology associations , 2009, Bioinform..

[16]  Y. Hamuro,et al.  Structure of the intact PPAR-γ–RXR-α nuclear receptor complex on DNA , 2008, Nature.

[17]  Allan Kuchinsky,et al.  Exploring Biological Networks with Cytoscape Software , 2008, Current protocols in bioinformatics.

[18]  S. Catalano,et al.  Peroxisome Proliferator-Activated Receptor-γ Activates p53 Gene Promoter Binding to the Nuclear Factor-κB Sequence in Human MCF7 Breast Cancer Cells , 2006 .

[19]  Oliver Fiehn,et al.  Pathway analysis of kidney cancer using proteomics and metabolic profiling , 2006, Molecular Cancer.

[20]  G. Muscat,et al.  Orphan nuclear receptors: therapeutic opportunities in skeletal muscle. , 2006, American journal of physiology. Cell physiology.

[21]  C. Hew,et al.  Proteomic Analysis of Colorectal Cancer Reveals Alterations in Metabolic Pathways , 2006, Molecular & Cellular Proteomics.

[22]  E. Espinosa,et al.  Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis. , 2005, Carcinogenesis.

[23]  C. Shapiro,et al.  Peroxisome Proliferator-Activated Receptor γ-Independent Ablation of Cyclin D1 by Thiazolidinediones and Their Derivatives in Breast Cancer Cells , 2005, Molecular Pharmacology.

[24]  K. Greulich,et al.  Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. , 2004, Genomics.

[25]  Salil K. Das,et al.  Expression of Mn-Superoxide Dismutase Gene in Nontumorigenic and Tumorigenic Human Mammary Epithelial Cells , 2004, Journal of biomedicine & biotechnology.

[26]  D. Crowe,et al.  A retinoid X receptor (RXR)-selective retinoid reveals that RXR-α is potentially a therapeutic target in breast cancer cell lines, and that it potentiates antiproliferative and apoptotic responses to peroxisome proliferator-activated receptor ligands , 2004, Breast Cancer Research.

[27]  C. Grommes,et al.  Antineoplastic effects of peroxisome proliferatoractivated receptor γ agonists , 2004 .

[28]  D. Gold,et al.  Activation of peroxisome proliferator-activated receptor gamma by a novel synthetic triterpenoid 2-cyano-3,12-dioxooleana-1,9-dien-28-oic acid induces growth arrest and apoptosis in breast cancer cells. , 2003, Cancer research.

[29]  M. Knowles,et al.  Proteomic changes in renal cancer and co‐ordinate demonstration of both the glycolytic and mitochondrial aspects of the Warburg effect , 2003, Proteomics.

[30]  D. Heber,et al.  Novel Therapeutic Approach: Ligands for PPARγ and Retinoid Receptors Induce Apoptosis in bcl-2-positive Human Breast Cancer Cells , 2002, Breast Cancer Research and Treatment.

[31]  K. Houseknecht,et al.  Peroxisome proliferator-activated receptor gamma (PPARγ) and its ligands: A review , 2002 .

[32]  I. Pass,et al.  Tumor suppressor and anti-inflammatory actions of PPARγ agonists are mediated via upregulation of PTEN , 2001, Current Biology.

[33]  J. Koutcher,et al.  ATP depletion + pyrimidine depletion can markedly enhance cancer therapy: fresh insight for a new approach. , 2000, Cancer research.

[34]  E. Brown,et al.  Expression of peroxisome proliferator‐activated receptors (PPARS) in human astrocytic cells: PPARγ agonists as inducers of apoptosis , 2000 .

[35]  P. Puigserver,et al.  Transcriptional regulation of adipogenesis. , 2000, Genes & development.

[36]  A. Mathur,et al.  Evaluation of fluorescent dyes for the detection of mitochondrial membrane potential changes in cultured cardiomyocytes. , 2000, Cardiovascular research.

[37]  E. Simpson,et al.  Peroxisome Proliferator-activated Receptor γ Ligands Inhibit Estrogen Biosynthesis in Human Breast Adipose Tissue: Possible Implications for Breast Cancer Therapy , 2000 .

[38]  David L. Steffen,et al.  The Breast Cancer Gene Database: a collaborative information resource , 1999, Oncogene.

[39]  V. Laudet,et al.  Fibrates increase human REV-ERBalpha expression in liver via a novel peroxisome proliferator-activated receptor response element. , 1999, Molecular endocrinology.

[40]  P. Libby,et al.  PPARγ Activation in Human Endothelial Cells Increases Plasminogen Activator Inhibitor Type-1 Expression PPARγ as a Potential Mediator in Vascular Disease , 1999 .

[41]  A Masini,et al.  Functional heterogeneity of an isolated mitochondrial population revealed by cytofluorometric analysis at the single organelle level. , 1996, Experimental cell research.

[42]  K. Umesono,et al.  Differential expression and activation of a family of murine peroxisome proliferator-activated receptors. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[43]  M. Rao,et al.  Cloning of a new member of the peroxisome proliferator-activated receptor gene family from mouse liver. , 1993, The Journal of biological chemistry.

[44]  Christine Dreyer,et al.  Control of the peroxisomal β-oxidation pathway by a novel family of nuclear hormone receptors , 1992, Cell.

[45]  T. Smith,et al.  J-aggregate formation of a carbocyanine as a quantitative fluorescent indicator of membrane potential. , 1991, Biochemistry.

[46]  I. Issemann,et al.  Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators , 1990, Nature.

[47]  S. Mazurek.  Pyruvate kinase M2: A key enzyme of the tumor metabolome and its medical relevance. , 2012 .

[48]  S. Catalano,et al.  Peroxisome proliferator-activated receptor-gamma activates p53 gene promoter binding to the nuclear factor-kappaB sequence in human MCF7 breast cancer cells. , 2006, Molecular endocrinology.

[49]  C. Grommes,et al.  Antineoplastic effects of peroxisome proliferator-activated receptor gamma agonists. , 2004, The Lancet. Oncology.

[50]  E. Simpson,et al.  Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: possible implications for breast cancer therapy. , 2000, Cancer research.

[51]  T. Sinohara,et al.  Expression of peroxisome proliferator-activated receptors (PPARS) in human astrocytic cells: PPARgamma agonists as inducers of apoptosis. , 2000, Journal of neuroscience research.

[52]  P. Libby,et al.  PPARgamma activation in human endothelial cells increases plasminogen activator inhibitor type-1 expression: PPARgamma as a potential mediator in vascular disease. , 1999, Arteriosclerosis, thrombosis, and vascular biology.

[53]  J. Reddy,et al.  Peroxisomal lipid metabolism. , 1994, Annual review of nutrition.

[54]  H. Keller,et al.  Control of the peroxisomal beta-oxidation pathway by a novel family of nuclear hormone receptors. , 1992, Cell.

[55]  S. Weinhouse.  On respiratory impairment in cancer cells. , 1956, Science.